Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

• Chemotherapy Induced Peripheral Neuropathy Treatment market size has reached to $1.75 billion in 2025 • Expected to grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Rising Cancer Prevalence Boosts Chemotherapy-Induced Peripheral Neuropathy Treatment Market • Market Trend: Innovation In Chemotherapy-Induced Peripheral Neuropathy Treatment Market • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Chemotherapy Induced Peripheral Neuropathy Treatment Market?

Chemotherapy induced peripheral neuropathy (CIPN) refers to a set of symptoms and complications that can develop because of certain chemotherapy drugs used in the treatment of cancer. It is a type of peripheral neuropathy, which involves damage or dysfunction of the peripheral nerves that connect the brain and spinal cord to the rest of the body. The main drug classes of chemotherapy induced peripheral neuropathy treatment are nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidant, and others. Nerve protective therapy refers to treatments or interventions aimed at preserving or safeguarding the health and function of nerves. Nerve protective therapy is utilized in the management of chemotherapy-induced peripheral neuropathy to help preserve nerve function and alleviate symptoms. The various treatments include medication, therapy, and others and the types of drugs are branded and generic. The chemotherapy induced peripheral neuropathy treatment drugs are sold at hospital pharmacies, retail pharmacies, online pharmacies, and others and the end-users include hospitals, research institutes, and specialty clinics.

What Is The Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Forecast?

The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing investment in targeted neuropathy therapies, rising focus on personalized oncology supportive care, expansion of clinical trials for cipn drugs, growing demand for quality-of-life improving treatments, advancements in biomarker-based diagnosis. Major trends in the forecast period include increasing focus on neuroprotective drug development, rising adoption of combination therapy approaches, growing emphasis on early diagnosis and symptom management, expansion of personalized treatment protocols, increasing clinical research on cipn management.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes 2) By Treatment: Medication, Therapy, Other Treatments 3) By Drug Type: Branded, Generic 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels 5) By End-User: Hospitals, Research Institutes, Specialty Clinics Subsegments: 1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine 2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine 4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10 5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies

What Is The Driver Of The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

The increasing prevalence of cancer is expected to propel the growth of the chemotherapy-induced peripheral neuropathy treatment market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. Chemotherapy-induced peripheral neuropathy is a potential side effect of certain chemotherapy drugs used in the treatment of cancer. The chemotherapy-induced peripheral neuropathy treatment market is subjected to grow as there is a rise of cancer cases globally. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, In 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the increasing prevalence of cancers driving the growth of the chemotherapy-induced peripheral neuropathy treatment market.

Key Players In The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends and Insights

Major companies involved in the chemotherapy-induced peripheral neuropathy treatment market are focused on innovating new products to improve their observation power and sustain their position in the market. For instance, in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, disclosed the FDA's approval of the Investigational New Drug Application (IND) for ATX01, their Phase 2 first-in-class candidate. This innovative treatment is intended for individuals with erythromelalgia. Meanwhile, the first patients in the ATX01 for the Pain of Chemotherapy (ACT) study of chemotherapy-induced peripheral neuropathy (CIPN) have been randomized. The FDA has given both programs fast-track designation.

What Are Latest Mergers And Acquisitions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

In August 2024, Pharmacosmos Group, a Denmark-based international healthcare company, acquired G1 Therapeutics for $405 million. This acquisition of Pharmacosmos Group aim is to expand and accelerate the availability of COSELA (trilaciclib), a treatment designed to reduce chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). G1 Therapeutics is a US-based biopharmaceutical company, specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.

Regional Outlook

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chemotherapy Induced Peripheral Neuropathy Treatment Market?

The chemotherapy induced peripheral neuropathy treatment market consists of sales of pharmaceutical drugs prescribed to alleviate chemotherapy-induced peripheral neuropathy symptoms. These drugs include pain relievers, antidepressants, anticonvulsants, and topical creams. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026?

The chemotherapy induced peripheral neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy induced peripheral neuropathy treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.